Oncology Central

Therapeutic targeting of tumor-associated macrophages and microglia in glioblastoma


Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor, accounting for approximately 15% of all primary brain tumors in adults. Despite therapeutic intervention involving surgical resection, ionizing irradiation (IR) and temozolomide, prognosis remains poor, with a median survival of 14.6 months, and a 5-year survival rate of only 3.3% [1]. Due in part to this dismal prognosis, GBM was one of the first diseases to be characterized by The Cancer Genome Atlas.

To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.